In the latest trading session,, 0.46 million Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) shares changed hands as the company’s beta touched 0.30. With the company’s most recent per share price at $0.51 changed hands at -$0.04 or -6.69% at last look, the market valuation stands at $34.99M. BCLI’s current price is a discount, trading about -560.78% off its 52-week high of $3.37. The share price had its 52-week low at $0.13, which suggests the last value was 74.51% up since then. When we look at Brainstorm Cell Therapeutics, Inc.’s average trading volume, we note the 3-month average coming to 1.02 million.

Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) trade information

Instantly BCLI was in red as seen in intraday trades today. With action -12.10%, the performance over the past five days has been red. The drop to weekly highs of 0.6700 subtracted -6.69% to the stock’s daily price. The company’s shares are showing year-to-date upside of 87.55%, with the 5-day performance at -12.10% in the red. However, in the 30-day time frame, Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) is 53.80% up. Looking at the short shares, we see there were N/A shares sold at short interest cover period of N/A days.

Brainstorm Cell Therapeutics, Inc. (BCLI) estimates and forecasts

Data shows that the Brainstorm Cell Therapeutics, Inc. share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 201.18% over the past 6 months, a 45.10% in annual growth rate that is considerably higher than the industry average of 13.10%. Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 10.57%.